We provide tools and technologies that streamline workflows – from scientific discoveries to new medicines.
The Genovis Group consists of Genovis AB, Sweden, and the wholly owned subsidiary Genovis Inc., USA. The company’s shares are listed on Nasdaq First North Growth Market. Find more information at Investor Relations.
Genovis offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Genovis enzyme products, SmartEnzymes™, are a unique selection of rapid and easy-to-use enzymatic tools designed to improve the efficacy and throughput in analytical or preparative workflows for complex biopharmaceuticals. The enzymes are used by scientists all over the world, and the innovative product formats facilitate the characterization, development, production, and quality control of biological drugs.
A cornerstone of Genovis’ R&D activities is customer relations that enable product development to meet customer needs. Just as valuable is the collaboration with academic groups that focus on characterizing new enzymes, developing new workflows, and antibodies for novel targets.
Our core values shape how we work together, how we support our customers, and how we approach new challenges. They reflect what matters to us as a company and help guide the decisions we make every day – from small, everyday choices to long-term direction.
They are not just something we talk about, but something we aim to live by in our daily work – contributing to a culture where collaboration, curiosity, and a strong sense of purpose come naturally.
Efficient Lys-C digestion is critical for reliable protein identification in modern proteomics workflows. Missed cleavages, incomplete protein digestion, and challenging sample types can quickly reduce confidence in downstream LC–MS analysis. To address these challenges, Genovis has launched LysCERATOR™, a new Lys-C enzyme for efficient, lysine-specific protein digestion — even under demanding conditions.
“At Genovis, we believe that nature’s innovations can be transformed into technologies that simplify researchers’ work. By developing innovative biological tools and technology platforms, we empower our customers to advance basic research, develop faster and more precise diagnostic tests, and ultimately enable new treatment methods for patients.”